Estudios Clínicos - Laboratorios Farma

Estudios Clínicos

En esta sección encontrará los estudios clínicos más recientes, los cuales avalan la calidad, eficacia y efectividad de los principios activos de nuestros medicamentos.

Sacubitrilo Valsartán

<img width="1948" height="2560" decoding="async" src="/wp-content/uploads/2024/11/Characteristics-Predictors-and-Clinical-Outcomes-in-heart-failure-with-reduced-ejection-fraction-according-to-a-1-year-LVEF-following-sacubitril-valsartan-treatment_page-0001-scaled.jpg" alt="" />

Characteristics, Predictors, and Clinical Outcomes in heart failure with reduced ejection fraction according to a 1 year LVEF following sacubitril valsartan treatment

<img width="1917" height="2560" decoding="async" src="/wp-content/uploads/2024/11/Uptitration-of-Sacubitril-Valsartan-and-Outcomes_page-0001-scaled.jpg" alt="" />

Uptitration of Sacubitril Valsartan and Outcomes

<img width="1275" height="1650" decoding="async" src="/wp-content/uploads/2024/10/Kidney-Outcomes-Following-Angiotensin-Receptor-Neprilysin-Inhibitor-vs-Angiotensin-Converting-Enzyme-Inhibitor-ARB-therapy-for-Thrombotic-Microangiopathy_pages-to-jpg-0001.jpg" alt="" />

Kidney Outcomes: ARNI vs. ACE Inhibitors

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/TRANSITION-Study-e1730842655933.png" alt="" />

TRANSITION Study

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/TITRATION-e1730842561617.png" alt="" />

TITRATION

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/PIONEER-HF.png" alt="" />

PIONEER HF

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/PARAGON-HF-e1730842753756.png" alt="" />

PARAGON HF

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/PARADIGM-HF-e1730842490660.png" alt="" />

PARADIGM-HF

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Docherty-PARADIGM-HF2-e1730842409424.png" alt="" />

Docherty PARADIGM HF2

Diabetes

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="786" height="1057" decoding="async" data-src="/wp-content/uploads/2023/06/Diabetic-Agents-From-Metformin-e1686336020478.png" alt="" /><noscript><img width="786" height="1057" decoding="async" src="/wp-content/uploads/2023/06/Diabetic-Agents-From-Metformin-e1686336020478.png" alt="" />

Diabetic Agents, From Metformin

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="791" height="1057" decoding="async" data-src="/wp-content/uploads/2023/06/EMPA-KIDNEY-e1686335997573.png" alt="" /><noscript><img width="791" height="1057" decoding="async" src="/wp-content/uploads/2023/06/EMPA-KIDNEY-e1686335997573.png" alt="" />

EMPA KIDNEY

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/Empagliflozin-in-Heart-Failure-with-a-Preserved-Ejection-Fraction-e1730839509965.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Empagliflozin-in-Heart-Failure-with-a-Preserved-Ejection-Fraction-e1730839509965.png" alt="" />

Empagliflozin in Heart Failure with a Preserved Ejection Fraction

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="789" height="1057" decoding="async" data-src="/wp-content/uploads/2023/06/Empare-reduced-en-espanol-JACC-e1686335813952.png" alt="" /><noscript><img width="789" height="1057" decoding="async" src="/wp-content/uploads/2023/06/Empare-reduced-en-espanol-JACC-e1686335813952.png" alt="" />

Empare reduced en español JACC

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1055" decoding="async" data-src="/wp-content/uploads/2023/06/EMPULSE-e1686335838370.png" alt="" /><noscript><img width="797" height="1055" decoding="async" src="/wp-content/uploads/2023/06/EMPULSE-e1686335838370.png" alt="" />

EMPULSE

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1055" decoding="async" data-src="/wp-content/uploads/2023/06/Gliflozins-From-Antidiabetic-Drugs-to-Cornerstone-in-Heart-e1686335854527.png" alt="" /><noscript><img width="797" height="1055" decoding="async" src="/wp-content/uploads/2023/06/Gliflozins-From-Antidiabetic-Drugs-to-Cornerstone-in-Heart-e1686335854527.png" alt="" />

Gliflozins From Antidiabetic Drugs to Cornerstone in Heart

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1047" decoding="async" data-src="/wp-content/uploads/2023/06/Safety-of-Empagliflozin-in-e1686335883911.png" alt="" /><noscript><img width="797" height="1047" decoding="async" src="/wp-content/uploads/2023/06/Safety-of-Empagliflozin-in-e1686335883911.png" alt="" />

Safety of Empagliflozin in

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="796" height="1057" decoding="async" data-src="/wp-content/uploads/2023/06/SGLT2-Inhibitors-Statins-or-ACE-Inhibitors-of-the-21st-Century-e1730839939290.png" alt="" /><noscript><img width="796" height="1057" decoding="async" src="/wp-content/uploads/2023/06/SGLT2-Inhibitors-Statins-or-ACE-Inhibitors-of-the-21st-Century-e1730839939290.png" alt="" />

SGLT2 Inhibitors Statins or ACE Inhibitors of the 21st Century

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="796" height="1055" decoding="async" data-src="/wp-content/uploads/2023/06/SGLT2-inhibitors-the-statins-of-the-21st-century.EHJ_.2022-e1730840556437.png" alt="" /><noscript><img width="796" height="1055" decoding="async" src="/wp-content/uploads/2023/06/SGLT2-inhibitors-the-statins-of-the-21st-century.EHJ_.2022-e1730840556437.png" alt="" />

SGLT2 Inhibitors the Statins of the 21st Century

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="789" height="1057" decoding="async" data-src="/wp-content/uploads/2023/06/The-EMPEROR-Reduced-Trial-e1730840688798.png" alt="" /><noscript><img width="789" height="1057" decoding="async" src="/wp-content/uploads/2023/06/The-EMPEROR-Reduced-Trial-e1730840688798.png" alt="" />

The EMPEROR Reduced Trial

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1057" decoding="async" data-src="/wp-content/uploads/2023/06/The-role-of-SGLT2-I-in-vascular-aging-e1686336036815.png" alt="" /><noscript><img width="797" height="1057" decoding="async" src="/wp-content/uploads/2023/06/The-role-of-SGLT2-I-in-vascular-aging-e1686336036815.png" alt="" />

The role of SGLT2 I in vascular aging

Insuficiencia Cardiaca

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/2022-AHA-ACC-HFSA-Guideline-for-ICC-resumen-e1730840840219.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/2022-AHA-ACC-HFSA-Guideline-for-ICC-resumen-e1730840840219.png" alt="" />

2022 AHA ACC HFSA Guideline for ICC resumen

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/Guia-ESC-2021-Full-text.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Guia-ESC-2021-Full-text.png" alt="" />

Guía ESC 2021 Full text

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/Guia-manejo-ICC-AHA-full-text-e1730840956449.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Guia-manejo-ICC-AHA-full-text-e1730840956449.png" alt="" />

Guía manejo ICC AHA full text

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/Iacoviello-Recent-advances-in-pharmacological-treatment-of-heart-failure-e1730841042470.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Iacoviello-Recent-advances-in-pharmacological-treatment-of-heart-failure-e1730841042470.png" alt="" />

Iacoviello – Recent advances in pharmacological treatment of heart failure

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/Rol-del-SRAA-en-ICC.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Rol-del-SRAA-en-ICC.png" alt="" />

ADA 2023 Pharmacologic Approaches

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="444" height="594" decoding="async" data-src="/wp-content/uploads/2024/11/Sodium-glucose-cotransporter2-SGLT2-inhibitors-for-adults-with-chronic-kidney-disease-a-clinical-practice-guideline.png" alt="" /><noscript><img width="444" height="594" decoding="async" src="/wp-content/uploads/2024/11/Sodium-glucose-cotransporter2-SGLT2-inhibitors-for-adults-with-chronic-kidney-disease-a-clinical-practice-guideline.png" alt="" />

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="443" height="594" decoding="async" data-src="/wp-content/uploads/2024/11/The-SGLT2-inhibitor-empagliflozin-in.png" alt="" /><noscript><img width="443" height="594" decoding="async" src="/wp-content/uploads/2024/11/The-SGLT2-inhibitor-empagliflozin-in.png" alt="" />

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors for adults with chronic kidney disease

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="435" height="595" decoding="async" data-src="/wp-content/uploads/2024/11/Efficacy-of-sodium-glucose-2-transporter.png" alt="" /><noscript><img width="435" height="595" decoding="async" src="/wp-content/uploads/2024/11/Efficacy-of-sodium-glucose-2-transporter.png" alt="" />

Efficacy of Sodium-Glucose 2 Transporter Inhibitors in Heart Failure With Preserved Ejection Fraction

Enfermedad Renal

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/Cardiorenal-Syndrome-Classification-Pathophysiology-Diagnosis-and-Treatment-Strategies-A-Scientific-Statement-From-the-American-Heart-Association-e1730841166467.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Cardiorenal-Syndrome-Classification-Pathophysiology-Diagnosis-and-Treatment-Strategies-A-Scientific-Statement-From-the-American-Heart-Association-e1730841166467.png" alt="" />

Cardiorenal Syndrome Classification Pathophysiology Diagnosis and Treatment Strategies A Scientific Statement From the American Heart Association

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/KDIGO-2022.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/KDIGO-2022.png" alt="" />

KDIGO 2022

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/Management-of-Heart-Failure-in-Patients-with-Chronic-Kidney-Disease-e1730841409288.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Management-of-Heart-Failure-in-Patients-with-Chronic-Kidney-Disease-e1730841409288.png" alt="" />

Management of Heart Failure in Patients with Chronic Kidney Disease

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/Synopsis-KDIGO-2022-e1730841492976.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Synopsis-KDIGO-2022-e1730841492976.png" alt="" />

Synopsis KDIGO 2022

<img data-lazyloaded="1" src="data:image/gif;base64,R0lGODdhAQABAPAAAMPDwwAAACwAAAAAAQABAAACAkQBADs=" width="797" height="1063" decoding="async" data-src="/wp-content/uploads/2023/06/Use-of-Glucose-Lowering-Agents-e1730841617197.png" alt="" /><noscript><img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Use-of-Glucose-Lowering-Agents-e1730841617197.png" alt="" />

Use of Glucose Lowering Agents

Sacubitrilo Valsartán

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/Docherty-PARADIGM-HF2-e1730842409424.png" alt="" />

Docherty PARADIGM HF2

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/PARADIGM-HF-e1730842490660.png" alt="" />

PARADIGM-HF

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/PARAGON-HF-e1730842753756.png" alt="" />

PARAGON HF

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/PIONEER-HF.png" alt="" />

PIONEER HF

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/TITRATION-e1730842561617.png" alt="" />

TITRATION

<img width="797" height="1063" decoding="async" src="/wp-content/uploads/2023/06/TRANSITION-Study-e1730842655933.png" alt="" />

TRANSITION Study

<img width="1275" height="1650" decoding="async" src="/wp-content/uploads/2024/10/Kidney-Outcomes-Following-Angiotensin-Receptor-Neprilysin-Inhibitor-vs-Angiotensin-Converting-Enzyme-Inhibitor-ARB-therapy-for-Thrombotic-Microangiopathy_pages-to-jpg-0001.jpg" alt="" />

Kidney Outcomes: ARNI vs. ACE Inhibitors

<img width="1917" height="2560" decoding="async" src="/wp-content/uploads/2024/11/Uptitration-of-Sacubitril-Valsartan-and-Outcomes_page-0001-scaled.jpg" alt="" />

Uptitration of Sacubitril Valsartan and Outcomes

<img width="1948" height="2560" decoding="async" src="/wp-content/uploads/2024/11/Characteristics-Predictors-and-Clinical-Outcomes-in-heart-failure-with-reduced-ejection-fraction-according-to-a-1-year-LVEF-following-sacubitril-valsartan-treatment_page-0001-scaled.jpg" alt="" />

Characteristics, Predictors, and Clinical Outcomes in heart failure with reduced ejection fraction according to a 1 year LVEF following sacubitril valsartan treatment

La información suministrada en este sitio web fue preparada por Laboratorios Farma S.A. y dirigida exclusivamente para el personal médico y profesionales de la salud. NO podrá ser considerado de uso general para las personas, ni como consejos médicos, recomendaciones o asesorías médicas de ningún tipo. Sugerimos no automedicarse y consultar previamente a su médico acerca de cualquier inquietud relacionada con la información de productos o fármacos que aquí se mencionen. Laboratorios Farma S.A. no será responsable por el mal uso que puedan darle terceras personas a la información aquí obtenida

© Todos los derechos reservados. 2025. Laboratorios Farma S.A. RIF J-00013393-0. Venezuela

© Todos los derechos reservados. 2025.

Laboratorios Farma S.A. RIF J-00013393-0. Venezuela

Sitio web desarrollado por WITS SEO